Details of the Drug

General Information of Drug (ID: DMQ789Z)

Drug Name
8H9
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Antibody
Cross-matching ID
PubChem CID
164575500
TTD ID
D06JAL
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tenascin (TNC) TTUCPMY TENA_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Brain cancer
ICD Disease Classification 2A00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tenascin (TNC) DTT TNC 2.41E-162 2.68 3.01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01502917) Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01099644) Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum. U.S. NationalInstitutes of Health.
3 In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24.